OIG Assessing Risk of Medicaid MCO Rebates on 340B-Purchased Drugs

by Admin | November 4, 2014 1:35 pm

November 4, 2014—The Department of Health and Human Services Office of Inspector General is assessing the risk of manufacturer discounts and rebates both being paid on 340B-purchased drugs dispensed to Medicaid managed care beneficiaries, the OIG said in its fiscal year 2015 work plan[1].  

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[2].    Already registered? Click here to login[3]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

 

Endnotes:
  1. fiscal year 2015 work plan: http://oig.hhs.gov/reports-and-publications/workplan/index.asp#current
  2. Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
  3. Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2014/11/oig-assessing-risk-of-medicaid-mco-rebates-on-340b-purchased-drugs/

Copyright ©2026 340binformed.org unless otherwise noted.